Augia Pharma gets FDA nod for generic Rheumatrex

Press enter to search
Close search
Open Menu

Augia Pharma gets FDA nod for generic Rheumatrex

By Sandra Levy - 02/04/2020

Patients with certain cancers, skin conditions, and arthritis, have a new generic treatment option. The Food and Drug Administration has given Aurobindo’s joint venture Eugia Pharma Specialties the green light for methotrexate tablets in a dosage strength of 2.5 mg.

Methotrexate tablets are the generic of Dava Pharmaceuticals’ Rheumatrex tablets. Eugia Pharma Specialties' product will be launched in March 2020.

The product has a market value of roughly $98 million for the 12 months ended December 2019, according to IQVIA.

Related Topics